Agenus Inc.
NASDAQ:AGENBiotechnology
-$0.01 today
- Market cap
- $289.58M
- Beta
- 1.54
- P/E (TTM)
- 1.7
- EPS (TTM)
- $1.70
Volume 0.88M
Average 0.82M
AGEN Other Current Assets
Current assets not reported separately, such as prepaid expenses.
Agenus Inc.NASDAQ: AGEN
Other Current Assets · Q1 FY2026 · quarter ended Mar 2026
Other current assets falls 15.9% from a year ago
Other current assets stood at $2.04M at the end of Q1 FY2026, down 15.9% from a year earlier and down 98.4% from the prior quarter.
Context
- Other current assets amounted to 1.1% of total assets at the end of Q1 FY2026, down 0.1 pp from a year earlier.
- Other current assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current assets keeps falling in the next quarterly balance sheet after a -15.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 128.61M USD
- Year-over-year change
- +5225.3%
| Period | Period end | Other Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 128.61M | +5225.3% |
| FY2024 | 2024-12-31 | 2.42M | +1.8% |
| FY2023 | 2023-12-31 | 2.37M | +122.3% |
| FY2022 | 2022-12-31 | (10.64M) | +38.1% |
| FY2021 | 2021-12-31 | (17.19M) | — |
Other Current Assets vs competitors
How AGEN compares with its peers on the latest reported figures
- AGEN's Mar 2026 other current assets of $2.04M is the 6th highest of the 10 companies compared; the peer median is $2.59M.
- Its year-over-year change of -15.9% is the 3rd highest of 8, against a peer median of -25.7%.
- Other current assets amounts to 1.1% of total assets for AGEN, versus a peer median of 1.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $6.34M | -39.2% | -28.3% | 2.5% | |
| Mar 2026 | $4M | -25.7% | -46.8% | 1.4% | |
IRDOpus Genetics, Inc. | Mar 2026 | $3.93M | +184.6% | +181.7% | 5.9% |
| Mar 2026 | $3.57M | -27.7% | +43.1% | 2.7% | |
| Mar 2026 | $2.59M | -17.1% | -3.4% | 1.0% | |
| Mar 2026 | $2.04M | -15.9% | — | 1.1% | |
| Mar 2026 | $1.16M | +1940.4% | +87.0% | 0.6% | |
| Mar 2026 | $367.51K | -47.7% | +36.9% | 1.2% | |
TTRXTurn Therapeutics Inc. | Mar 2026 | $235.17K | — | — | 1.3% |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding AGEN) | $2.59M | -25.7% | +36.9% | 1.3% | |
Competitors are the stored peer set for AGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 291.93M | 178.67M | 76.11M | 40.44M | 3M |
| Short-term Investments | 14.99M | 14.68M | 0 | 0 | 0 |
| Net Receivables | 1.52M | 2.74M | 25.84M | 407K | 1.83M |
| Inventory | 20.36M | 13.83M | 0 | 0 | 0 |
| Other Current Assets | (17.19M) | (10.64M) | 2.37M | 2.42M | 128.61M |
| Total Current Assets | 331.97M | 213.12M | 112.42M | 45.57M | 133.44M |
| Property, Plant & Equipment (Net) | 91.08M | 164.29M | 163.03M | 147.4M | 24.25M |
| Goodwill | 24.88M | 25.47M | 24.72M | 24.09M | 24.09M |
| Intangible Assets | 8.49M | 6.23M | 4.41M | 3.38M | 3.04M |
| Long-term Investments | 0 | 0 | 3.22M | 4.64M | 42.73M |
| Tax Assets | (2.67M) | (2.67M) | 0 | 0 | 0 |
| Other Non-current Assets | 12.21M | 7.12M | 6.11M | 1.19M | (742K) |
| Total Non-current Assets | 133.98M | 200.43M | 201.5M | 180.7M | 93.36M |
| Total Assets | 465.96M | 413.56M | 313.91M | 226.27M | 226.8M |
| Account Payables | 30.49M | 40.94M | 61.45M | 61.47M | 82.99M |
| Short-term Debt | 728K | 575K | 146K | 2.7M | 155.11M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 12.43M | 12.27M | 18K | 31K | 1.14M |
| Other Current Liabilities | 75.66M | 101.49M | 141.21M | 121.85M | 83.11M |
| Total Current Liabilities | 156.94M | 188.95M | 255.9M | 221.4M | 323.49M |
| Long-term Debt | 12.82M | 12.58M | 12.77M | 30.47M | 169.66M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 11.2M | 1.14M | 1.14M | 1.14M | 1.14M |
| Other Non-current Liabilities | 194.97M | 202.45M | 125.26M | 225.13M | 242K |
| Total Non-current Liabilities | 261.11M | 279.51M | 206.4M | 311.29M | 181.17M |
| Total Liabilities | 418.05M | 468.46M | 462.3M | 532.7M | 504.66M |
| Common Stock | 2.57M | 3.06M | 3.94M | 236K | 353K |
| Retained Earnings | (1.49B) | (1.71B) | (1.96B) | (2.18B) | (2.18B) |
| Accumulated OCI | 1.49M | 915K | (955K) | (1.4M) | (439K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 13.47M | 6.38M | 11.95M | 19.96M | (6.75M) |
| Total Equity | 47.91M | (54.9M) | (148.38M) | (306.42M) | (277.86M) |
| Total Debt | 58.29M | 78.43M | 93.19M | 94.87M | 334.9M |
| Net Debt | (233.64M) | (100.25M) | 17.08M | 54.43M | 331.9M |
Agenus Inc.
NASDAQ:AGEN
Intrinsic Alpha fair value
Locked
Current Price
$6.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.